MiNK Therapeutics, Inc. (INKT) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
149 Fifth Avenue
New York City, NY 10010
United States of America (the)
Phone
212 994 8250
Website
Sector
Healthcare
Industry
Biotechnology
Employees
23
First IPO Date
October 15, 2021
| Name | Title | Pay | Year Born |
| Jennifer S. Buell | Co-Founder, President, CEO & Director | 803,686 | 1975 |
| Terese C. Hammond | Head of Inflammatory & Pulmonary Diseases | 0 | N/A |
| Melissa Orilall | Principal Financial Officer | 0 | 1989 |
| Garo H. Armen | Executive Chairman | 0 | 1953 |
| Austin Charette | Principal Accounting Officer | 0 | 1989 |
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.